MICC:EURONEXT AMSTERDAMMagnum Ice Cream Co. N.V. Analysis
Data as of 2026-07-28 - not real-time
$18.04
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The stock is trading at $18.04, just below its 20‑day simple moving average but comfortably above the 50‑day and 200‑day averages, indicating a still‑positive longer‑term trend. RSI sits near the midpoint at 51, suggesting no immediate overbought or oversold pressure, while the MACD histogram is negative, pointing to short‑term bearish momentum. Recent Q1 2026 results showed a solid start with €1.77 bn revenue and a 4.5% organic sales lift, providing a modest earnings uplift despite a full‑year revenue decline of 4.1%. The company carries a high debt load (over €3.4 bn) and a debt‑to‑equity ratio above 500, which limits financial flexibility. Valuation metrics are stark: the discounted‑cash‑flow model implies a fair value near $2.78, far below the current price, and the forward P/E of about 15 contrasts sharply with a trailing P/E of 33, highlighting a price that may be stretched. Market sentiment is exuberant, with the Fear & Greed Index in “Extreme Greed” territory, yet analyst coverage is thin and recent downgrades signal caution. Overall, the blend of a bullish long‑term price position, modest operating margins, and a heavily leveraged balance sheet creates a nuanced risk‑reward profile.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price marginally below 20‑day SMA and bearish MACD histogram
- Stable trading volume but high valuation gap
- Recent Q1 earnings beat but full‑year revenue decline
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Positive organic sales growth in Q1 and improving forward earnings
- Price above 50‑day and 200‑day SMAs indicating sustained trend
- Potential upside perceived by analysts despite current overvaluation
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Consumer defensive sector provides resilience
- High leverage could constrain future cash generation
- Valuation disparity suggests limited upside unless debt is reduced
Key Metrics & Analysis
Financial Health
Revenue Growth-4.10%
Profit Margin3.70%
P/E Ratio32.8
ROE17.88%
ROA8.72%
Debt/Equity539.65
P/B Ratio15.5
Op. Cash Flow$483.0M
Free Cash Flow$365.6M
Technical Analysis
TrendBullish
RSI51.7
Support$17.24
Resistance$19.14
MA 20$18.29
MA 50$17.30
MA 200$16.13
MACDBearish
VolumeStable
Fear & Greed Index87.46
Valuation
Fair Value$2.78
Target Price$17.53
Upside/Downside-2.85%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.41
Volatility28.60%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.